Clinical data on Idorsia's pipeline compounds will be presented at the European Society of Cardiology Congress 2019
August 23, 2019 11:35 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – August 23, 2019 Idorsia Ltd (SIX: IDIA) today announced that data from Phase 2 studies with aprocitentan, a new dual endothelin receptor antagonist, and selatogrel, a...
Clinical data on Idorsia's pipeline compounds will be presented at the European Society of Cardiology Congress 2019
August 23, 2019 11:35 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – August 23, 2019 Idorsia Ltd (SIX: IDIA) today announced that data from Phase 2 studies with aprocitentan, a new dual endothelin receptor antagonist, and selatogrel, a...
Janssen reports positive top-line Phase 3 results for ponesimod in adults with relapsing multiple sclerosis
July 26, 2019 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Data are part of the OPTIMUM study comparing the efficacy and safety of ponesimod and Aubagio® in adults with relapsing multiple sclerosisIdorsia Pharmaceuticals Ltd, J&J and Actelion...
Janssen reports positive top-line Phase 3 results for ponesimod in adults with relapsing multiple sclerosis
July 26, 2019 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Data are part of the OPTIMUM study comparing the efficacy and safety of ponesimod and Aubagio® in adults with relapsing multiple sclerosisIdorsia Pharmaceuticals Ltd, J&J and Actelion...
Idorsia gibt Finanzergebnisse für das erste Halbjahr 2019 bekannt
July 23, 2019 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Schweiz – 23. Juli 2019 Idorsia Ltd (SIX: IDIA) gab heute die Finanzergebnisse für das erste Halbjahr 2019 bekannt. Wichtige Updates US GAAP-Betriebsaufwand im ersten...
Idorsia announces financial results for the first half of 2019
July 23, 2019 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – July 23, 2019 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2019. Key figures US GAAP operating expenses HY 2019 at CHF 252...
Efficacy and safety data with Idorsia's dual orexin receptor antagonist presented at SLEEP 2019 in San Antonio
June 13, 2019 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – June 13, 2019 Idorsia Ltd (SIX: IDIA) today announced that efficacy and safety data from two Phase 2 studies of ACT‑541468, Idorsia's dual orexin receptor antagonist,...
Efficacy and safety data with Idorsia's dual orexin receptor antagonist presented at SLEEP 2019 in San Antonio
June 13, 2019 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – June 13, 2019 Idorsia Ltd (SIX: IDIA) today announced that efficacy and safety data from two Phase 2 studies of ACT‑541468, Idorsia's dual orexin receptor antagonist,...
Zweite ordentliche Generalversammlung von Idorsia - Alle Anträge des Verwaltungsrates angenommen
May 03, 2019 07:25 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Schweiz - 3. Mai 2019An der heute in Basel, Schweiz, abgehaltenen Generalversammlung von Idorsia Ltd (SIX: IDIA) stimmten die Aktionäre allen Vorschlägen des Verwaltungsrates mit grosser...
Idorsia holds its second Annual General Meeting of Shareholders - All Board proposals approved
May 03, 2019 07:25 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland - May 3, 2019At today's Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted in favor of all proposals by the Board of...